Pretreatment of CAV Combination Chemotherapy with Tropisetron Shows Less Cardio and Neurotoxicity Side Effects in Rats

Abstract

Tropisetron, a 5-HT3 antagonist receptor, is commonly used for the prevention of emesis following chemotherapy. Lines of evidence point to the anti-inflammatory and immune modulatory properties of tropisetron. The current study aims to investigate whether tropisetron is able to prevent the cardiotoxicity and neurotoxicity induced by doxorubicin (DOX) and vincristine besides its anti emetic effect in a co-administration protocol, since this combination therapy is widely used in various combination chemotherapy regimens. Jour n a l o f C linical T o x ic o log y